Please login to the form below

Not currently logged in
Email:
Password:

Bioequivalence study triggers milestone payment for Eurand

Eurand completes a bioequivalence study with GlaxoSmithKline regarding an undisclosed GSK compound

Eurand, an Italian/ US-based specialty pharmaceutical company, has successfully completed a bioequivalence study with GlaxoSmithKline (GSK), regarding an undisclosed GSK compound. 

UK-headquartered GSK will make a payment of USD 1.5m to Eurand in recognition of the milestone.

The new formulation, which uses Eurand's Microcaps and AdvaTab technologies, is designed to dissolve quickly in the mouth to reduce the bitter taste of some medications. Eurand could potentially receive milestone payments from GSK totalling up to USD 42m for the development of the product. GSK expects to file an NDA in the near future.

Under the agreement, Eurand will manufacture the product for GSK and receive royalty revenues when the product receives NDA approval from the FDA.

Gearoid Faherty, CEO of Eurand, said: "We are delighted with the results of the bio-study and are looking forward to GSK submitting their NDA."

4th September 2007

Share

Featured jobs

Subscribe to our email news alerts

PMHub

Add my company
Just::Health Communications

Just:: is a different kind of healthcare communications agency. Since 2006, we’ve been collaborating with clients around the world to...

Latest intelligence

04 A Healthy Ambience
Creating a Lifeline to the New Digital User...
03 Health Services
How Pharma Companies Can Survive the Patent Cliff Through Digital Innovation...
From lay summaries to patient engagement programmes: how patient-centricity is finally becoming a reality
How pharma is progressing their commitment in patient engagement...

Infographics